Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Cancer Nurs. 2017 May-Jun;40(3):184–193. doi: 10.1097/NCC.0000000000000381

Figure 4.

Figure 4

EBRT did not alter the integrity of blood-brain-barrier. Compared to the baseline (T1) S100B concentrations did not change at midpoint of EBRT (T2) or at one year after treatment completion (T3). Results suggest that EBRT dosage received by study participants did not result in disturbances in the blood-brain-barrier. Values are mean ± SEM.